SGO Issues March 7, 2019

SGO Issues March 7, 2019

Online schedule for 2019 SGO Annual Meeting now available
Donate to the ALL IN campaign today and double your impact
Call for abstracts: Rare gynecologic tumors and conditions
FWC announces Board of Directors appointments
Upcoming Gynecologic Cancer Education Courses
Mentors updated for Annual Meeting Speed Mentoring session

Online schedule for 2019 SGO Annual Meeting now available

The full online schedule for the SGO Annual Meeting on Women’s Cancer, March 16-19, in Honolulu, HI, is now available on the SGO50.org website. All abstract titles and author strings are listed and abstract embargos will be lifted on the morning that the abstracts are presented. A printable PDF version of the schedule is also available on the SGO50 website, but the online version will be the most up-to-date.

Donate to the ALL IN campaign today and double your impact

Now through March 19—the last day of the Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer—all new donations of $50 or more to the ALL IN campaign will be matched up to $50,000 thanks to the generosity of an anonymous donor. Donate to help boost GYN cancer patient education and outreach, promote your subspecialty so it’s easy for women to find gynecologic oncologists in their area, and to support the research of young investigators and ensure the long-term success of gynecologic oncology. To commemorate 50 years of SGO, consider donating $50 for every year you’ve been a member at bit.ly/AllInFWC or by texting SGO to 41444.

Attending SGO’s Annual Meeting in Honolulu, HI? Donors will receive an exclusive ALL IN ribbon during registration and have their names prominently displayed on digital monitors throughout the meeting.

Call for abstracts: Rare gynecologic tumors and conditions

For a special issue of Gynecologic Oncology, to be published in conjunction with SGO’s 2020 Annual Meeting on Women’s Cancer, physicians and scientists who are engaged in the study of rare gynecologic tumors—pre-malignant or malignant—are invited to submit an original manuscript reporting their results or review article for peer review. Published papers will investigate the epidemiology, etiology, biology, prevention, risk factors, pathology, diagnosis, treatment, and prognosis of rare gynecologic tumors and rare conditions associated with gynecologic tumors. Send abstracts for review to Linda Brooks, Publishing Support & Insights Specialist for Gynecologic Oncology at l.brooks@elsevier.com. Abstracts need to be submitted by Friday, April 5, 2019.

Relevant topics include (but are not limited to):

  1. Basic and translational studies of rare gynecologic tumors, including genetics, immunology, biology, cell signaling pathways, or mutational analyses.
  2. Pathology of rare gynecologic tumors.
  3. Epidemiology of rare gynecologic tumors, including race and ethnicity differences.
  4. Prevention of rare gynecologic tumors.
  5. Pre-malignant gynecologic tumors and their impact on the development of invasive cancers.
  6. Clinical trial methodology related to the study of rare gynecologic tumors.
  7. Clinical trials for rare gynecologic tumors, including innovative therapies (targeted therapeutics, immune therapies).
  8. Treatment strategies based on histological types across organs.
  9. Fertility preservation in the management of rare gynecologic tumors.
  10. Observational studies on the treatment of rare gynecologic tumors.
  11. Methodology other than clinical trials—programs, centers of excellence, consortia, cancer registries, databases, etc.—to study rare gynecologic tumors.
  12. National or international efforts to develop guidelines for the treatment of rare gynecologic tumors.
  13. Outcomes and prognostic factors associated with rare gynecologic tumors.
  14. Conditions associated with rare gynecologic tumors—e.g. paraneoplastic syndrome, hereditary syndromes, etc.
  15. Health services research related to rare gynecologic tumors.
  16. Patient perspectives related to rare gynecologic tumors.

The issue’s guest editors are David M. Gershenson, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; Aikou Okamoto, MD, PhD, The Jikei University School of Medicine, Tokyo, Japan; and Isabelle Ray-Coquard, MD, PhD, Centre Leon Berard, University Claude Bernard Lyon I, Lyon, France. 

FWC announces Board of Directors appointments

Ginger Gardner, MD

The Society of Gynecologic Oncology and Foundation for Women’s Cancer Boards of Directors and the 2018 Nominating Committee, congratulates the following SGO members who were appointed to serve on the Foundation Board: Chair-Elect Ginger J. Gardner, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Chair of Communications Committee Joshua Kesterson, MD, Penn State College of Medicine, Hershey, PA; Director-At-Large, Chad A. Hamilton, MD, Inova Schar Cancer Institute, Annandale, VA. The new members of the FWC Board of Directors will begin their terms after the SGO Annual Meeting.

Upcoming Gynecologic Cancer Education Courses

The Foundation for Women’s Cancer (FWC) has scheduled two free education courses this spring for all gynecologic cancer patients, survivors, partners, family members, friends and anyone else interested in hearing from leading U.S. experts in gynecologic cancer treatment and research. The next course will be held March 15 from 9:00 a.m. to 4:00 p.m. at the Hawaii Convention Center in Honolulu, HI, during the SGO Annual Meeting pre-conference sessions. The University of Texas MD Anderson Cancer Center will host an education course on May 3. To learn more about hosting an education course at your institution, contact Megan Stankewicz at megan.stankewicz@sgo.org or 312-637-3438.

Mentors updated for Annual Meeting Speed Mentoring session

More than 250 attendees of the SGO 2019 Annual Meeting on Women’s Cancer are registered to attend the Diversity and Inclusion Task Force’s Speed Mentoring Session at 12:30 p.m. March 18. An updated list of mentors and topics features 29 mentors addressing seven topics selected to help attendees navigate their careers.